SPEED UP YOUR VACCINE DEVELOPMENT
LabChip® GXII Touch™ Instruments
The coronavirus, SARS-CoV-2, outbreak has highlighted the need for rapid vaccine development. This complex task requires a high throughput, standardized and reliable screening tool to qualify potential candidates and to ensure quality control.
The automated LabChip® GXII Touch™ protein characterization system and LabChip® GX Touch™ nucleic acid analyzer support rapid, reliable and quantitative protein and nucleic acid analysis. The LabChip® platform supports SARS-CoV-2 vaccine development through the analysis of protein source material used in several technologies under evaluation as potential SARS-CoV-2 vaccines, including nucleic acid and protein subunit strategies.
“Microfluidic chips produced results comparable to those of gels but with much lower sample consumption, facilitating assay miniaturization for scarce biological samples. The time savings afforded by microfluidic electrophoresis and automatic quantification has allowed us to incorporate microfluidic ABPP early in the drug discovery workflow, enabling routine assessments of tissue distribution and engagement of targets and off-targets in vivo.”
Abide Therapeutics, SLAS Technology. 2019:24 p489
Subunit vaccines for both SARS coronaviruses involve the production of coronavirus S-spike proteins (S-protein). To facility S-protein sizing analysis, screening and quality control, the LabChip® GXII Touch™ protein characterization system automates destaining, electrophoretic separation, and fluorescent detection on a microfluidic chip, eliminating the need for SDS-PAGE analysis or HPLC. Protein samples are analyzed in less than a minute with a sample consumption of less than 5 microliters.
The LabChip® GXII Touch™ Protein Characterization system is ideal for SARS-CoV-2 protein subunit vaccine development. This system enables high-throughput protein sizing and quantification to support:
- Recombinant subunit expression optimization and tracking
- Subunit purification tracking
- Formulation development- excipient assessment, purity, stability, modification, aggregation, and degradation
- Product Quality Assessment- purity, stability, modification, aggregation, and degradation
- Virus like particle (VLP) characterization
Advanced nucleic acid vaccine platforms for SARS-CoV-2 include both RNA and DNA technologies. The LabChip® GX Touch™ nucleic acid analyzer is the industry leading technology for high-throughput sizing and quantification of mRNA, RNA and DNA. The LabChip® GX Touch™ system generates high quality quantitative data in the form of a virtual gel, electropherogram, and table summary following electrophoretic separation and fluorescent detection of nucleic acids.
The LabChip® GX Touch™ nucleic acid analyzer is a versatile tool for screening nucleic acid source material in the development of SARS-CoV-2 vaccine candidate development, including mRNA, RNA and DNA. The system enables this process by performing:
- Plasmid library screening
- Endpoint PCR analysis
- Clonal library stability
- RNA expression studies
For research use only. Not for use in diagnostic procedures.